VanEck Biotech ETF (NASDAQ:BBH) Shares Sold by Comerica Bank

Comerica Bank decreased its stake in shares of VanEck Biotech ETF (NASDAQ:BBH) by 10.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 821 shares of the company’s stock after selling 99 shares during the quarter. Comerica Bank’s holdings in VanEck Biotech ETF were worth $129,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Janney Montgomery Scott LLC purchased a new stake in VanEck Biotech ETF in the 4th quarter worth approximately $481,000. Flagship Harbor Advisors LLC boosted its stake in VanEck Biotech ETF by 12.1% in the 4th quarter. Flagship Harbor Advisors LLC now owns 1,984 shares of the company’s stock worth $311,000 after buying an additional 214 shares during the last quarter. Strategic Financial Concepts LLC acquired a new stake in VanEck Biotech ETF in the 4th quarter worth about $3,828,000. Commonwealth Retirement Investments LLC purchased a new stake in VanEck Biotech ETF in the 4th quarter valued at about $215,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of VanEck Biotech ETF during the 4th quarter valued at about $81,000. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Stock Performance

VanEck Biotech ETF stock opened at $145.53 on Monday. VanEck Biotech ETF has a 1 year low of $135.34 and a 1 year high of $183.64. The firm has a 50 day moving average price of $150.67 and a 200 day moving average price of $158.92. The company has a market cap of $333.26 million, a price-to-earnings ratio of 24.26 and a beta of 0.85.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.